The latest report from business information and analytics provider, GlobalData, has indicated that immune-oncology (IO) will become the fifth pillar of cancer treatment, joining surgery, radiotherapy, chemotherapy and other targeted treatments.
Cancer
To generate actionable insights, GlobalData’s health team analysed more than 4,000 clinical trials and over 800 IO products in Phase I–III clinical trials. The report, ‘Pharma Focus Visual Analysis of Immuno-Oncology Development and Opportunities’, focuses mainly on developments in active immunotherapy products based on their molecular targets and molecule types. Additionally, immune checkpoint modulators, along with 18 solid tumour types and eight blood cancers, were assessed.